Irinotecan
Anaplastic Mixed Oligoastrocytoma
City of Hope Medical CenterSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Anaplastic Mixed Oligoastrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Patrick Y. Wen, MD | Phase 2 | B |
Tandutinib National Cancer Institute (NCI) | Phase 2 | B |
Carboplatin National Cancer Institute (NCI) | Phase 2 | B |
Zactima National Cancer Institute (NCI) | Phase 2 | B |
Talampanel Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | CCC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →